Some safety net hospitals are gaming a federal drug discount program to boost profits, according to a report by Community Oncology Alliance (COA).
The group says disproportionate share hospitals (DSH) participating in the 340B Drug Pricing Program charge nearly four times their acquisition costs for expensive oncology drugs, and pocket the margins.
Since 1992, the 340B program has required drug manufacturers to provide significant discounts on outpatient drugs for qualifying institutions that